City hospital signs MoU with Teleflex to create a UroLift Center of Education for South Asia
Fortis Hospitals, Bengaluru, recently signed a Memorandum of Understanding (MoU) with Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies to create UroLift Center of Education for South Asia in India.
The UroLiftTM System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life.
'The UroLiftTM System is a BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue. The UroLiftTM System provides rapid symptom relief and preserves sexual function. Typically, no catheter is required after the treatment,' said the press release.
'Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex.
Dr. Mohan Keshavamurthy, Principal Director – Renal Sciences, Fortis Hospitals, Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Wire
12 hours ago
- The Wire
Noah Holdings and ARK Wealth Outline Strategic Wealth Allocation Framework for Navigating Market Volatility at Financial Forums in Hong Kong
HONG KONG, June 6, 2025 /PRNewswire/ — Noah Holdings Limited ('Noah' or the 'Company') (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-stop advisory services on global investment and asset allocation primarily for global Chinese high-net-worth investors, and its internationally focused subsidiary, ARK Wealth Management, delivered key strategic … Continue reading "Noah Holdings and ARK Wealth Outline Strategic Wealth Allocation Framework for Navigating Market Volatility at Financial Forums in Hong Kong"
Economic Times
19 hours ago
- Economic Times
Stablecoin bigwig Circle soars in debut on the New York Stock Exchange
The US-based issuer of one of the most popular cryptocurrencies made its debut on the New York Stock Exchange on Thursday and quickly saw its value soar amid heavy interest from crypto enthusiasts and investors. Circle Internet Group issues USDC, a stablecoin that can be traded at a 1-to-1 ratio for US dollars, and EURC, which can similarly be traded for euros. Stablecoins are a fast-growing corner of the cryptocurrency industry that offer a buffer against volatility because they are pegged to real-world assets, like US dollars or gold. That makes them a much more reliable means of conducting commercial transactions than other forms of crypto. Interest in Circle's initial public offering is high. The company's underwriters priced the offering at $31 per share Wednesday, up from an expected range of $27 to $28. The number of shares being sold was raised to 34 million from 32 million. Circle is listed on the NYSE under the symbol "CRCL." The stock price soared above $96 at one point Thursday afternoon and landed at $83.23 by closing. Circle's initial public offering is one of the biggest public listings for a crypto-related company since the exchange Coinbase went public in 2021. The dominant player in the stablecoin field is El Salvador-based Tether, which has the stablecoin known as USDT that currently has about $150 billion in circulation. USDC is the second most popular stablecoin market cap, with about $60 billion in circulation. Circle said in a regulatory filing that USDC has been used for more than "$25 trillion in onchain transactions" since its launch in 2018. Revenue-wise the company has seen tremendous growth, going from just $15 million in 2020 to $1.7 billion in 2024. Stablecoin issuers make profits by collecting the interest on the assets they hold in reserve to back their stablecoins. Circle said USDC is backed by "cash, short-dated US Treasuries and overnight US Treasury repurchase agreements with leading global banks." Circle's IPO comes amid a push by the Trump administration and the crypto industry to pass legislation that would regulate how stablecoin issuers operate in the US A Senate bill advanced last month with bipartisan support. There is also growing competition in the stablecoin field. A crypto enterprise partly owned by the Trump family just launched its own stablecoin, USD1. Circle said its long track record and values - the company says its mission statement is "to raise global economic prosperity through the frictionless exchange of value" - will help it stand apart in the field.
Time of India
20 hours ago
- Time of India
Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a strategic collaboration with Alvotech , a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda ( pembrolizumab ) for global markets. 'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange filing. Keytruda, a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars market. This partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive activity. Under the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain exceptions. The deal is expected to accelerate development timelines and expand the global market reach of the biosimilar. Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing expertise. With this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment. 'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's. Dr. Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE. Also read: Positive Breakout: These 5 stocks cross above their 200 DMAs ( Disclaimer : Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
